GBA's "2021 Stock Phantasma"

Surface Oncology’s SRF617 gets FDA orphan drug status
Mar. 30, 2021 4:35 PM ETSurface Oncology, Inc. (SURF)
  • Surface Oncology (NASDAQ:SURF)announces that theU.S. FDA has granted Orphan Drug Designation for one of the company’s lead therapeutic candidates,SRF617, for the treatment of patients with pancreatic cancer.
  • Programs with Orphan Drug status receive partial tax credit for clinical trial expenditures, waived user fees and eligibility for seven years of marketing exclusivity.
  • In preclinical studies, SRF617 has exhibited strong affinity for and inhibition of CD39, the ability to reduce adenosine and increase ATP levels and anti-tumor activity both as a single agent and in combination with multiple therapeutic agents, the company said.
  • Shares up nearly 6% after market.
Example of a good stk in a bad market stock has been down ever since we grabbed it. -16% in 5 days. Up 13%in the pre.-
 
  • Biden's plan reportedly will include $650B toward U.S. infrastructure including roads, bridges, highways and ports, plus hundreds of billions of dollars to bolster the electric grid, enact nationwide high-speed broadband and revamp the country's water systems to ensure clean drinking water, among other major investments.
  • The plan also is said to include ~$400B toward care for the elderly and the disabled, $300B for housing infrastructure and $300B to revive U.S. manufacturing.
 
Urban-Gro reports Q4 EPS (24c) vs (57c) last year

Jefferies starts Clarivate at Buy, sees CEO 'just getting warmed up' 07:48 CLVT

OneSpan initiated with a Buy at DA Davidson as revenue growth accelerates 07:48 OSPN

Jefferies starts Chimerix at Buy with $21 price target » 07:42 CMRX

Acreage Holdings opens third The Botanist dispensary in New Jersey 07:39 ACRHF Acreage Holdings announced the opening of The Botanist Williamstown - a medical cannabis dispensary - in Williamstown, New Jersey. With the opening of The Botanist Williamstown, located at 2090 N Black Horse Pike, Acreage now operates three dispensaries in New Jersey, which is the maximum allowable by state law. Acreage's two other dispensaries are in Egg Harbor Township at 100 Century Drive and in Atlantic City at 1301 Boardwalk located on the iconic Atlantic City Boardwalk.

Aemetis receives LCFS pathway approval utilizing dairy biogas for renewable fuel 07:36 AMTX Aemetis announced that it has received certification from the California Air Resources Board for a new LCFS Tier 2 fuel pathway for the Aemetis Advanced Fuels Keyes ethanol production plant utilizing renewable dairy biogas as a process energy input. The new pathway reduces the carbon intensity of Aemetis' fuel ethanol from 67.3 to 65.6 utilizing dairy biogas from two dairies with an average CI score of negative 426. Aemetis began operating two anaerobic dairy digesters and a 4-mile private pipeline in September 2020 near the company's ethanol biorefinery in Keyes, California. The new ethanol pathway certification from CARB is effective as of October 1, 2020. The Aemetis Central Dairy Digester Project is a collection of dairy lagoon anerobic digesters that are built, owned, and operated by Aemetis Biogas LLC utilizing waste animal manure to generate renewable methane gas to produce negative carbon intensity RNG for transportation use to displace petroleum diesel fuel. An estimated 25% of methane emissions in California is produced by dairy waste lagoons. Once complete, the Aemetis Central Dairy Digester Project is expected to include over 30 dairy digesters in the current phase, and utilize 36 miles of private pipeline owned by Aemetis, a centralized gas clean up unit located at the Aemetis Keyes ethanol biorefinery, a Renewable Natural Gas onsite fueling station, and an interconnection to PG&E's natural gas pipeline. The company plans to begin construction of the next five dairy digesters and the additional 32 miles of biogas pipeline in Q2, with five more dairy digesters set to begin construction in Q3 and five digesters beginning in 1Q22, for a planned total of seventeen dairy digesters and a 35-mile biogas pipeline in operation by 2Q22.
 
Delcath Systems initiated with a Buy, $24 target at Canaccord 03/09 <------
DCTH
Canaccord Genuity analyst Arlinda Lee initiated coverage of Delcath Systems with a Buy rating and $24 price target. Delcath's Hepzato, a combination drug and device liver-directed therapy, has established efficacy, but has not achieved U.S. regulatory approval due to its safety profile in earlier iterations, Lee tells investors in a research note. With "multiple measures" to mitigate safety issues into the ongoing Phase 3 FOCUS trial in ocular melanoma patients with liver metastases, and with multiple Orphan designations, the analyst is "cautiously optimistic" Hepzato can show a positive efficacy-safety profile. Improved safety measures studies bode well for potential new drug application re-filing in 2022, says the analyst.

This AM-->Delcath Systems Inc trading halted, news dissemination
 
stonedinvestor said:
Paysafe completes business combination with Foley Trasimene Acquisition Corp. II 07:30 PSFE, BFT Paysafe Group Holdings…
More...
Today is ticker change day! On Aeva's ticker change day, it opened up for trading on the Webull app (and so I figured Robinhood also) at about 10:30am I think, and that's when the biggest spike happened. It will be interesting to see what Paysafe does when it opens for trading.
 
Hydrofarm price target lowered to $77 from $88 at Deutsche Bank 06:49 HYFM Deutsche Bank analyst Kevin Marek lowered the firm's price target on Hydrofarm to $77 from $88 and keeps a Buy rating on the shares. Management's 2021 guidance of 20%- 25% core growth comes in ahead of pre-earnings consensus, while the 6.8%-7.2% adjusted EBITDA guidance put consensus at the low end, Marek tells investors in a research note. Show Relat

Teradyne guidance could reverse share underperformance, says Deutsche Bank 06:46 TER

STONEY's MOST FRUSTRATING STOCK. AVTR!- The single stock with the most good news that never ever goes anywhere 1 year same price!!!!!! It seems!!!!! A couple times I have come close to booting it-- but I always stop myself last second and say you don't sell a stk for not moving. It's not their fault nobody understnds or knows of the company... it's just my personal misery.

Avantor reiterated as top pick in life science tools at Citi 06:23 AVTR Citi analyst Patrick Donnelly continues to view Avantor as one of the best positioned stocks across his coverage and the life science tools sector. The company has "tangible" growth and margin drivers that should deliver "meaningful upside" to guidance and consensus estimates over the next several quarters, Donnelly tells investors in a research note. As its leverage profile comes down and margins continue to migrate closer to peer levels, the case for multiple expansion improves, says the analyst. Donnelly reiterates Avantor as his top pick. Show Related Items >>

PUT AVTR IN YOUR IRA AND DON'T LOOK********
 
This was a $2 swing trade yesterday... I mentioned it as a great chart.. should of dug a little deeper.

A)DXC Technology Company (DXC)
NYSE - NYSE Delayed Price. Currency in USD

$31.14+2.60 (+9.11%)
At close: March 30 4:03PM

B) ELF Beauty is a BUY we scooped some yesterday looking for more today--
e.l.f. Beauty, Inc. (ELF)
NYSE - NYSE Delayed Price. Currency in USD
$27.04+0.46 (+1.73%)
At close: March 30 4:00PM EDT
$29.08+2.04 (7.55%)<-----------------
Pre-Market:8:10AM EDT




CohBar price target raised to $3.50 from $3.00 at Chardan
 
You must log in or register to reply here.
Back
Top